NCT07562152

Atebimetinib + GnP as a First Line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma

Recruiting · Phase 3 · Immuneering Corporation · registry updated 2026-11-06

Inclusion and exclusion lines below are quoted from ClinicalTrials.gov. No match score is shown, because a score needs a person's age, biomarkers, and treatment dates. Confirm the record with the study team.

The purpose of this study is to evaluate the safety and efficacy of atebimetinib in combination with modified GnP compared with SOC GnP alone.

Inclusion

Must be ≥18 years of age
Must have confirmed diagnosis according to AJCC staging as follows:
Metastatic pancreatic adenocarcinoma within 12 weeks prior to screening
Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
Participants must be treatment naive as follows:
First-line PDAC participants will have received no previous systemic anti-cancer therapy

Exclusion

Inability to swallow oral medications
Participant has squamous, adenosquamous, neuroendocrine (carcinoid, islet cell) or acinar pancreatic carcinoma
Participants with only locally advanced disease
Symptomatic, untreated, or actively progressing known central nervous system (CNS) metastases

Open NCT07562152 on ClinicalTrials.gov All conditions